Alzheimer Disease
A-beta immunization reduced cerebral volume in Alzheimer disease
Published in Clinical Trials Week, July 18th, 2005
According to recent research from England and the United States, "Alzheimer disease (AD) is characterized by progressive cerebral atrophy that may be measured using MRI. Reported are MRI findings of a Phase IIa immunotherapy trial in AD prematurely terminated owing to meningoencephalitis in a subset of patients.
"The study objective was to assess cerebral volume changes in patients immunized with AN1792 (beta-amyloid [A-beta] 1 to 42) who were antibody responders (anti-AN1792 IgG titer of {{>=}} 1:2,200) compared with placebo patients. This randomized, multicenter,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2005-07-18)
More Articles from Clinical Trials Week
- Angiology
U.S. trial for atrial fibrillation underway - Anorexia Nervosa
Alendronate shows promise for treatment of osteopenia - Headache and Migraine
Almotriptan effective in patients with poor response to sumatriptan - Pain Management
Leading institution will study promise of a new antimicrobial benefit of ON-Q - Acute Vertebrobasilar Occlusion
IV Abciximab, intra-arterial rtPA, and additional PTA/stenting improve outcome - Adrenalectomy
Transperitoneal and retroperitoneal approaches to adrenalectomy evaluated - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
